|By Marketwired .||
|June 19, 2014 09:30 AM EDT||
NEW YORK, NY -- (Marketwired) -- 06/19/14 -- Daxor Corporation (NYSE MKT: DXR) -- The Board of Directors of Daxor Corporation, at its June 18, 2014 meeting, renewed its annual stock buy-back program of up 250,000 shares.
The Board of Directors also voted to explore options for partnering with a much larger company to facilitate acceptance of its unique medical services and technology. The focus will be on a large company with experience in distribution and marketing. The company intends to engage an investment banker to expedite this process. As part of this process, the Board of Directors is also willing to consider a partial sale of the company.
The company remains committed to its fundamental goal of making its blood volume analyzer a standard of care in medical and surgical conditions. Daxor's BVA-100 is the only semi-automated instrument approved by the FDA for direct blood volume measurement.
Accurate knowledge of a patient's blood volume is essential to determining who should receive a transfusion and who should not receive a transfusion. For example, the President of Daxor, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 and had emergency surgery. He lost approximately 10 times as much blood as was estimated by the surgeon and anesthesiologist. The actual blood loss was documented by a subsequent blood volume measurement which demonstrated the true extent of the severe blood loss. Fortunately Dr. Feldschuh also had a unit of his own frozen blood available which had been collected four-and-a-half years previously and was administered shortly after the surgery when he experienced symptoms due to the blood loss.
Blood loss is just one example of where precise knowledge of a patient's blood volume is essential, but is unavailable in most hospitals in the United States. Congestive heart failure, the #1 expense for Medicare patients admitted to hospitals in the United States, is primarily a blood volume derangement. A study published from the Mayo Clinic in the Journal of the American College of Cardiology - Heart Failure documented that congestive heart failure patients are a specific group requiring significantly different modes of treatment depending on the underlying blood volume derangement. At the present time patients are not routinely treated utilizing blood volume measurements. The death rate for congestive heart failure patients is 30 to 40% within one year of hospitalization for heart failure.
Renal dialysis patients, patients with hypertension, syncopy patients (fainting), are common conditions where blood volume derangements are essential to understanding the pathology of the patients. Patients are routinely treated for these conditions on the basis of surrogate tests which have been shown to be inaccurate.
A fundamental goal of the company is to make blood volume measurement a standard of care so that patients are optimally treated, particularly in conditions with high death rates and permanent, severe complications.
The company has also pioneered the use of frozen autologous (self storage) blood. Such blood stored at super-low temperatures can be used for up 2 to 10 years after collection. The American Medical Association has stated that "the only safe blood is one's own blood." Despite the obvious benefits of such a program, this service has minimal utilization.
Additional information and analyst evaluation of Daxor is available on our website www.daxor.com.
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Aug. 27, 2016 12:45 AM EDT Reads: 2,920
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Aug. 27, 2016 12:45 AM EDT Reads: 2,136
Aug. 27, 2016 12:15 AM EDT Reads: 2,250
Aug. 26, 2016 11:15 PM EDT Reads: 1,743
Aug. 26, 2016 10:45 PM EDT Reads: 2,057
Aug. 26, 2016 10:00 PM EDT Reads: 1,838
Aug. 26, 2016 09:15 PM EDT Reads: 1,425
Aug. 26, 2016 07:15 PM EDT Reads: 396
Aug. 26, 2016 07:00 PM EDT Reads: 652
Aug. 26, 2016 07:00 PM EDT Reads: 697
Aug. 26, 2016 06:00 PM EDT Reads: 1,924
Aug. 26, 2016 05:00 PM EDT Reads: 668
Aug. 26, 2016 04:45 PM EDT Reads: 1,532
Aug. 26, 2016 04:30 PM EDT Reads: 2,309
Aug. 26, 2016 04:00 PM EDT Reads: 3,932